Outline Epidemiology: Global and U.S. How are we doing in terms of goals of treatment? Updates in the fast moving field of HIV medicine EPIDEMIOLOGY
|
|
- Jacob Jefferson
- 5 years ago
- Views:
Transcription
1 Updates in the fast moving field of HIV medicine 35 th Advances in Infectious Diseases April 25, 2014 Monica Gandhi MD, MPH Professor of Medicine and Clinic Director ( Ward 86 ), Division of HIV/AIDS San Francisco General Hospital Outline Epidemiology: Global and U.S. How are we doing in terms of goals of treatment? HIV testing: When and how often? HIV Prevention: Where are we in 2014? Post exposure prophylaxis HIV Treatment: When to start and updates in 2014 HIV cure: Berlin, the Baby, Boston and Brie EPIDEMIOLOGY 1
2 Major news from UNAIDS update 9/23/13 Case GOOD NEWS 1.6 million died from HIV 2012, from 2.3 million 2001 New HIV infections among adults by 50% in 26 countries b ,000 children infected 2012 (330, ) BAD NEWS 75 million infected since epidemic started, 36 million have died Although 9.7 million have access to ARVs, only 34% of people who qualify Any child being infected 26 yo married woman presents to your 1 o care practice for pre conception visit. She has had sex with men only and has had 3 partners in her life. You tell her that you will be sending an HIV test today in addition to routine pre conception labs and she tells you to not bother as she doesn t think she is at risk for HIV infection. What percentage of the HIV population in U.S. is not aware of their HIV infection? % % % % % CDC estimates 1,148,200 persons in U.S. 13 yrs living with HIV, including 207,600 (18.1%) unaware 2
3 % HIV diagnosis attributable to MSM in 2011 (account for >half in all but 2 states) HIV Testing and Risk Behaviors Among Gay, Bisexual, and Other Men Who Have Sex with Men MMWR Nov 2013 / 62(47); % 25.1% Case (continued) 74.9% U.S. Census 2011 estimates: 13% Black/African American 17% Hispanic/Latino 78% White 25.1% The patient s rapid HIV Ab test returns as positive, as does her urine pregnancy test. Blood tests verify both findings. She is happy about the pregnancy, but upset about the HIV diagnosis and said she never thought she could be at risk. She also asks if this means that her husband knew about the diagnosis but was not taking medications. 3
4 The Course of Untreated HIV Infection: CD4 cells and HIV RNA What percentage of the HIV population in U.S. has achieved the goal of therapy (complete virologic suppression)? Seeding of latent reservoirs CD8 cytotoxic T cells 1. 82% 2. 66% 3. 50% 4. 33% 5. 25% CDC vital statistics July 2012: The patient looks terrible Medical Monitoring Project (MMP) 3 surveillance datasets. Testing, linkage, retention, prescription and adherence rates all contribute to poor virologic suppression rate in this country ( Cascade of Care ) TESTING Of the 1.1 million Americans living with HIV, only 25% are virally suppressed 4
5 How often should a patient be tested at UCSF for HIV infection? 1. Once, then every time the patient reports risk factors 2. Once every 2 years and with reported risk factors 3. Once yearly and with reported risk factors 4. Once every 6 months and with reported risk factors 5. Every admission CDC 9/21/06 risk-based to routine HIV screening in all health care settings yrs after patient notified (opt out screening assent inferred unless patient declines) 1. HIV testing for those high risk at least qyear No written consent, relaxed prevention counseling Pregnancy: Screen in 1 st trimester, repeat in 3 rd trimester if risk factors Routine testing still called grade C recommendation by USPSTF up to April 30, 2013 Branson BM et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings.mmwr Recomm Rep Sep 22;55(RR 14):1 17 ; 2 Wynia MK. Routine screening: informed consent, stigma and the waning of HIV exceptionalism. Am J Bioeth Jul Aug;6(4):5 8; 3 Burke RC et al. Why don't physicians test for HIV? A review of the US literature. AIDS U.S. Preventative Services Task Force Recommendations changed April 2013 Routine testing once for everyone age ( grade A recommendation) Paves way for coverage under ACA Repeat testing based for Those higher risk for HIV infection Those actively engaged in risky behavior Those living in high prevalence setting Orasure test FDA approved for home testing 5/15/12 FDA panel recommended (17 0) first in home over the counter saliva test kit (OraQuick In Home HIV test ) Specificity 99.98%; sensitivity 92.98% (false negative rate of concern) Cost ~$60; use at least 90 days after exposure Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, April 30,
6 Case (continued) PREVENTION The patient asks whether there was anything she could have done to protect herself from HIV infection (even while trying to conceive) if she had known her no good husband s status. Of the following interventions, which has the highest efficacy (level I RCT data) in preventing heterosexual HIV transmission? 1. Microbicides 2. Circumcising the male partner 3. Pre exposure prophylaxis for HIV negative partner 4. HIV vaccine 5. Using HIV treatment for HIV+ partner 6. Post exposure prophylaxis for HIV negative partner Of the following interventions, which has the highest efficacy (level I RCT data) in preventing HIV transmission? 1. Microbicides Jury out (CAPRISA 004 yes on 1% tenofovir gel; VOICE no with same product) 2. Circumcising the male partner (Yes, helps men; no efficacy for women partners) 3. Pre exposure prophylaxis for HIV negative partner 4. HIV vaccine (no viable candidate; recent failures) 5. Using HIV treatment for HIV+ partner 6. Post exposure prophylaxis for HIV partner 6
7 PrEP Adherence everything, esp in women Pre exposure prophylaxis: PrEP Preexposure prophylaxis (PrEP) is giving an HIVnegative individual a pill (daily, or coitally?) to prevent HIV infection (studied: Tenofovir +/ emtricitabine) Trial Population/Setting Intervention iprex [1] (N = 2499) Partners PrEP [2] (N = 4747) TDF2 [3] (N = 1219) Bangkok TFV Study [6] (N= 2413) FEM PrEP [4] (N = 2120) VOICE [5] (N = 5029) MSM, 11 sites in US, S. America, Africa, Thailand Serodiscordant couples in Africa Heterosexual males and females in Botswana IDU (use in last year) in Bangkok High risk women, Africa High risk women, Africa Reduction in HIV Infection Rate, % Daily oral TDF/FTC 44% (95% CI 15 63, p 0.005) Daily oral TDF Daily oral TDF/FTC Daily oral TDF/FTC Women: 71%; men: 63% Women: 66%; men: 84% 62%* (underpowered for sex differences) Daily oral TDF 49% (95% CI , p 0.01) Daily oral TDF/FTC Daily oral TDF Daily oral TDF/FTC 1% TFV gel Study stopped early due to futility 1% TDF gel & daily oral TDF arm both stopped early, futile Daily TDF/FTC arm no efficacy Grant RM, et al. N Engl J Med. 2010;363: Baeten JM, et al. N Engl J Med. 2012;367: Thigpen MC, et al. N Engl J Med. 2012;367: Van Damme L, et al. N Engl J Med. 2012;367: ; 5. Marrazzo J, et al. CROI 20th, March 4, 2013, Atlanta, GA; 6. ChoopanyaK et al. Lancet June 2013: 381: 9883: PrEP approved July 2012 by FDA Treatment as prevention Voted 19 3 in favor of Truvada as PrEP for MSM Heterosexual women and men in serodiscordant partnerships Other individuals at risk for HIV infection Some controversy Behavioral disinhibition, relies on adherence, side effects, should be focusing on treatment Only 20% of HIV+ pts in low or middle income countries know status Model predicts reduction of HIV incidence & mortality to <1 case/1000 people in 10 yrs (prevalence to <1% within 50 yrs) Rights, feasibility, costs all concerns Granich RM et al. Jan 2009:373:48-57 MMWR 2012; 61: ; MMWR 2011; 60: de Cock AM et al. Can antiretroviral therapy eliminate HIV transmission?; 2 Garnett GP et al. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet; Jan
8 HPTN 052 Study Design Stable, healthy, serodiscordant couples, sexually active CD4 count: 350 to 550 cells/mm 3 (Africa, Asia, Americas) Randomization Immediate ART CD Delayed ART CD4 <250 Cohen MS et al. Prevention of HIV 1 infection with early antiretroviral therapy. NEJM August 2011 (HPTN 052) Primary Transmission Endpoint Transmission events that were linked to that primary partnership Primary Clinical Endpoint WHO stage 4 clinical events, pulmonary tuberculosis, severe bacterial infection and/or death The Data safety and monitoring board announced April 28, 2011 HPTN 052: HIV 1 Transmission Total HIV-1 Transmission Events: 39 The Board recommends that the results of the trial be announced as soon as possible (was supposed to go until 2014) HPTN 052 continues to follow couples, but all HIVinfected participants are being offered ART Immediate Arm: 1 Linked Transmissions: 28 p < % reduction Delayed Arm: 27 Unlinked or TBD Transmissions: 11 People have sex outside of their partnerships.. 23/28 (82%) transmissions in sub Saharan Africa 18/28 (64%) transmissions from female to male partners 238 pregnancies People have unprotected sex. 8
9 Occupational exposure PEP Fluid Risks Blood Semen/vaginal CSF, synovial, pleural, pericardial, amniotic Feces, saliva, nasal, sputum, sweat, tears, urine, vomitus Percutaneous: 0.3% (95% CI %) rate (deep vs superficial; large bore vs not; blood in tip or not; HIV end stage or not but still offer if viral load suppressed) Mucous membrane/non intact skin: 0.09% (95% CI %) infection rate CDC guidelines: last updated 9/2013 Kuhar DT. Infection Control and Hospital Epidemiology 2013; 34(9); Risk Yes Yes, not occupational Unknown (presumed) No, unless bloody New guidelines for PEP - Simple Decide on case by case basis Try within 72 hours of exposure (1 week if high risk) 28 days Tenofovir + emtricitabine + raltegravir (no 2 drug vs 3 drug PEP) well tolerated, minimal interactions and resistance (consult expert if?) No nevirapine Follow up testing at 6 wks, 12 wks and done at 6 months (4 months if 4 th generation combination HIV p24 antigen HIV antibody test available) Kuhar DT. Infection Control and Hospital Epidemiology 2013; 34(9); Case (cont.) TREATMENT The patient is very worried about her fetus and asks about her baby s chances of getting HIV now that she knows she is infected 9
10 What is rate of maternal to child transmission of HIV (with appropriate management) in 2014 in the U.S.? 1. 25% 2. 10% 3. 5% % 5. <1% Case (cont.) At your recommendation, the patient decides to start antiretroviral therapy right away in the context of pregnancy. Her CD4 and viral load is pending. She asks you If I wasn t pregnant, doc, when would you suggest I start HIV therapy? What are the current U.S. guidelines on when to start antiretroviral therapy? 1. As soon as the patient is diagnosed with HIV 2. When CD4 count 200 cells/mm 3 3. When CD4 count 350 cells/mm 3 4. When CD4 count 500 cells/mm 3 5. When the HIV RNA level (viral load) >100,000 copies/ml When to Begin Treatment for asymptomatic patients - U.S. guidelines 3/27/12 & 2/13/13 HIV Infection ART is recommended for all HIV positive individuals Prior to 3/12, start when CD4 count <500 Universal ART policy adopted in San Francisco through HIV Division leadership (Havlir, Hare) and SFDPH January 2010 DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents; Available at: March 27, 2012 and February 13,
11 What are the current W.H.O. guidelines on when to start antiretroviral therapy? 1. As soon as the patient is diagnosed with HIV 2. When CD4 count 200 cells/mm 3 3. When CD4 count 350 cells/mm 3 4. When CD4 count 500 cells/mm 3 5. When the HIV RNA level (viral load) >100,000 copies/ml W.H.O. guidelines June 30, 2013 >500 Don t treat Asymptomatic CD4+ T cells/mm 3 HIV Infection <500 Treat Prior to 6/30/13, start when CD4 count <350 All children <5 yrs, pregnant and breastfeeding women, HIV in relationship with HIV+, active HepB or TB Treat W.H.O. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection", June 30, 2013 (updated guidelines) Was there ever a clinical trial that randomized patients to starting HIV therapy upon diagnosis versus CD4 <500? 1. Yes how could the recommendations have changed otherwise? 2. No Recommendations changed due to pathogenesis Given toxicities, one idea was to reduce total duration on therapy by going off and on Strategies for Management of Antiretroviral Therapy (SMART) Eligibility: CD4> 350 (N=5472) Continuous Treatment Baseline CD4: CD4 nadir: % < 400 copies/ml viral load: 71% Mean follow-up: 14 months (2% LFU) No Treatment until CD4 <250, then treatment until >350, then stop The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count guided interruption of antiretroviral treatment. NEJM
12 SMART Study Balance now tipped (permanently) on earlier treatment Progression of Disease/Death 164 Death 84 Serious HIV events 21 Severe non-hiv Complications 114 (Cardiac/CVA/renal/hepatic) Increased risk for all clinical outcomes, including death, HIV and non-hiv events with interrupted therapy # Events Relative Risk (95% CI) Favors off and on Favors continuous therapy WHY WAIT? Avoid drug-related toxicity Preserve future drug options Delay development of drug resistance WHY NOT WAIT? Possibility of irreversible immune system depletion Drugs easier to take now Increased possibility of progression to AIDS Increased risk of HIV transmission Some observational cohort data showing survival advantage HIV as chronic inflammatory condition more CV disease, CA, hepatic, renal Therapies now available for HIV infection Therapies now available for HIV infection 3) Integration Integrase 4) Transcription RT 5) Translation 6) Cleavage DNA 2) Reverse transcriptase RNA 1) Virus Entry CD4 receptor (CXCR4, CCR5) 9) Re-infection 3) Integration Integrase inhibitors 4) Transcription DNA Nucleoside reverse transcriptase RT inhibitors 2) Reverse transcriptase (NRTIs) RNA Nonnucleoside reverse transcriptase inhibitors (NNRTIs) 5) Translation Protease inhibitors 6) Cleavage 1) Virus Entry Fusion (entry) inhibitors (T20, CD4 envelope receptor protein gp41) (CXCR4, CCR5) CCR5 9) receptor Re-infection antagonist Protease 8) Maturation 8) Maturation 7) Packaging 7) Packaging 12
13 Many options... Fewer toxicities Nucleoside and nucleotide RTIs Zidovudine, AZT (Retrovir) Abacavir, ABC (Ziagen) Lamivudine, 3TC (Epivir) Didanosine, ddi (Videx) Stavudine, d4t (Zerit) Tenofovir, TFV (Viread) Emtricitabine, FTC (Emtriva) Combivir (AZT/3TC) Trizivir (AZT/3TC/ABC) Epzicom (3TC/ABC) Truvada (FTC/TFV) CCR5 receptor blocker Maroviroc (Selzentry) Integrase inhibitor Raltegravir (Isentress) Elvitegravir (ELV) Dolutegravir NNRTI s: Delavirdine (DLV) Nevirapine, NVP (Viramune) Efavirenz, EFV (Sustiva) Etravirine (Intelence) Rilpivirine (Edurant) Fusion inhibitors: Enfuvirtide, ENF or T20 (Fuzeon) SPC (1 pill once daily) Atripla (EFV/FTC/TFV) Complera (RPV/FTC/TFV) Stribild (ELV/cobicistat/TDF/ FTC) Protease inhibitors: Indinavir, IDV (Crixivan) Saquinavir, SQV (Invirase, hgc) Nelfinavir, NFV (Viracept) Amprenavir, APV (Agenerase) Atazanavir, ATZ (Reyataz) Fosamprenavir, FPV (Lexiva) Kaletra (lopinavir/ritonavir) Tipranavir (Aptivus) Darunavir (Prezista) red combination agents Circled DHHS recommended ARVs for naives What to start DHHS guidelines Preferred regimens Efavirenz/ tenofovir/emtricitabine (Atripla ) Raltegravir + tenofovir/emtricitabine (Truvada ) Elvitegravir/cobicistat/tenofovir/emtricitabine (Stribild ) Dolutegravir + abacavir/lamivudine (Epzicom ) Dolutegravir + tenofovir/emtricitabine Ritonavir + atazanavir + tenofovir/emtricitabine Ritonavir + darunavir + tenofovir/emtricitabine DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents; Available at: February 13, 2013; Update October 30, 2013 What to start WHO guidelines (updated 6/30/13) Preferred regimens Efavirenz + tenofovir + emtricitabine (Atripla ) Efavirenz + tenofovir + lamividudine (generic FDC) 9.7 million currently being treated worldwide Under WHO guidelines of treating CD4 <350, 17 million in need Now 26 million in need of treatment (only 34% getting) Case (cont.) The patient would like to start on a regimen that is new, has few pills and won t hurt my baby. You decide to just tell her and this audience about the newest medication available for HIV infection since there is not time to go over all 30 13
14 What is the name of the newest drug approved for the treatment of HIV infection in adults? 1. Darunavir 2. Maraviroc 3. Elvitegravir 4. Dolutegravir 5. Something vir Dolutegravir New integrase inhibitor, approved 8/12/13 by FDA n HIV infected adults and children > 12, 40kg Once daily, pregnancy class B Broad indications naives (SINGLE, SPRING 2, FLAMINGO studies), treatment experienced without integrase inhibitor resistance (SAILING study) treatment experienced with integrase inhibitor resistance (to RAL and ELV; VIKING 3 study) latter group 50mg po bid Pharmacokinetic bioequivalence :ABC/3TC + dolutegravir vs. single pill combination (SPC) Walmsley S. NEJM 2013; Raffi F. et al. Lancet 2013 (48 wks), Lancet ID (96 weeks); Cahn P. Lancet 2013 (48 wks); Eron JJ. JID 2013 & Castagna JID 2014; Clotet B. Lancet 2014 HIV and single pill combinations Which SPCs are available? HIV may be the perfect disease for an SPC given Need for multiple pills Can t be started sequentially; must be simultaneous Stigma, depression, other adherence barriers can make multiple pill taking difficult Mistakes in taking one pill and not another can lead to resistance TFV/FTC/Efavirenz (Atripla ), approved 2006 TFV/FTC/Rilpivirine (Complera ), approved 2011 TFV/FTC/elvitegravir/ cobicistat (Stribild ), approved 2012 ABC/3TC/dolutegravir (maybe 2014?) 14
15 If you are the most optimistic person ever, how many people in the world have been cured of HIV? Many The Mississippi Baby 28 month old child (now 37 mo) born at 35 weeks gestation (2.5kg) via NSVD Rapid HIV test positive in mother during labor (CD4 644; viral load 2423 copies/ml) No antiretrovirals in labor (precipitous delivery) HIV viral load (~20,000 copies/ml) at 30 hours of age AZT/3TC/NVP (usually 1 drug) started as prophylaxis by 31 hours of age (31 hrs 7d), therapeutic dose of NVP used; latter switched to LPV/r (protease inhibitor) (7d 18 months) after 1 week Persaud. NEJM
16 Typical biphasic decay Persaud. NEJM 2013 What happened to baby? Mother and baby lost to follow up when baby 18 months old Baby off treatment Re appeared ~24 months Plasma HIV RNA remained undetectable (off therapy) Super low HIV DNA in PBMC, no infectious virus ( graveyard sequences) No Western blot reactivity for child (remains reactive for mother) Baby (~42 months) still negative (CROI March, 2014) Another baby in Long Beach treated within 4 hours of birth no HIV at 9 months (still on ARVs) CD4+ T cells/mm Year RNA copies/ml 14 patients in France cured? Visconti trial 14 pts diagnosed with primary HIV infection (acute) late 90 s early 00s (12 pts symptoms) Started on standard ART < 10 weeks, continued x 3 years, then interrupted (6 9.6 years out) 14 patients ( post treatment controllers ) 8 with no detectable viremia off treatment (6/14 have occasional blips ) Early treatment meant low resting CD4 sets (but inducible) is this cure? Sáez Cirión A, Plos Pathogen patients cured s/p stem cell transplants, Boston Boston cure? 2 HIV+ men on ARVs with lymphoma Allogeneic stem cell transplants (donors didn t have CCR5 32 deletions) After STCs, host cells <0.001% of PBMCs, on sirolimus Continued ARVs for 2 and 5 years longer, then d/c d July 3, 2013: 9 and 27 weeks after stopping, no HIV RNA in bloodstream December 6, 2013: Virus reported to have come back in both (12 and 32 weeks) 16
17 Cure research initiative (Steve Deeks) Strategies being pursued Early ART may be curative Stem cell transplants to reduce reservoir Drugs to flush out HIV from latent reservoirs Vaccines to enhance host clearance Barriers anticipated Current ART not fully suppressive No high through put reliable assays to examine reservoir Flush out drugs may not work as monotherapy 17
HIV Update: Looking Forward, Where are we going? Outline
HIV Update: Looking Forward, Where are we going? 11 th HIV Network Nursing Conference May 15, 2015 Monica Gandhi MD, MPH Professor of Medicine and Medical Director ( Ward 86 ), Division of HIV/AIDS San
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationNothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationOutline. HIV in 2017 GLOBAL EPIDEMIOLOGY. When was the first report describing AIDS released? Epidemiology: Global U.S.
Outline HIV in 2017 March 22, 2017 Advances in Infectious Diseases Monica Gandhi MD, MPH Professor of Medicine Division of HIV, Infectious Diseases, and Global Medicine Medical director, Ward 86 HIV Clinic,
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationOutline. Update in the Fast Moving World of HIV HISTORY AND GLOBAL EPIDEMIOLOGY. When was the first report describing AIDS released?
Outline Update in the Fast Moving World of HIV April 21. 2016 Advances in ID Monica Gandhi MD, MPH Professor of Medicine Division of HIV, Infectious Diseases, and Global Medicine Medical director, Ward
More informationBlood-Borne Pathogens and Post-Exposure Prophylaxis
Blood-Borne Pathogens and Post-Exposure Prophylaxis Christopher Behrens MD Northwest Association of Occupational and Environmental Medicine October 2017 with thanks to Shireesha Dhanireddy MD Disclosures
More informationSingle Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era
Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon
More informationApproach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationHIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationPrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV
PrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV Laura Beauchamps, MD Assistant Professor Division of Infectious Diseases University of Mississippi Medical Center Principal Investigator
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationNew Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationDr Valérie Martinez-Pourcher
Educa&ng Nurses About An&retrovirals and HIV Preven&on - State of the Science, Uptake Challenges, and Barriers Dr Valérie Martinez-Pourcher Pitié-Salpêtrière Hospital Paris We need to control HIV replication
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationMalaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh
Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationcontinuing education for pharmacists
continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to
More informationInformation, inspiration and advocacy for people with HIV/AIDS and hepatitis C
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C p1 p5 p6 p7 HIV CARE NEWS New drugs: dolutegravir, MK-1439, cenicriviroc, and HIV and heart health. HIV PrEP NEWS Disappointing
More informationOverview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research
Overview of HIV Christina Polyak, MD, MPH Research Physician U.S. Military HIV Research Program, Walter Reed Army Institute of Research The views expressed are those of the authors and should not be construed
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationStructured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007
Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationMidwestern Underwriting Conference 2016
UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationThe New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
More informationPage 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions
Harvard-Brazil Collaborative Public Health Field Course January 2014 Lecture # 8 Building specialized knowledge: HIV Aluisio Segurado Department of Infectious Diseases School of Medicine, University of
More informationWorld AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary
World AIDS Day 2014 Year-by-Year Milestones in HIV/AIDS (Adapted from The POZ Timeline: Milestones in the HIV/AIDS Pandemic with additions compiled by Eric Brus, Director of HIV Health Promotion, AIDS
More informationNON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days
NON-OCCUPATIONAL POST EXPOSURE PREVENTION when you think you were exposed to hiv within the past three days A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationFundamentals of Antiretroviral Therapy
Fundamentals of Antiretroviral Therapy Southeast AIDS Education & Training Center HIV Clinical Overview 12 May 2016 Todd Hulgan, MD, MPH Department of Medicine, Division of Infectious Diseases Vanderbilt
More informationOB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION
OB/GYN CHART REVIEW A summary of OB/GYN clinical chart review results designed to monitor the quality of care provided by a Ryan White funded OB/GYN primary care site as part of the Atlanta EMA s quality
More informationAntiretroviral Pregnancy Registry
Preterm Birth, low birth weight and fetal antiretroviral exposure: Estimated gestational age and birth weight data from singleton live births, 1989 through 31 January 2009 K. Beckerman, J. Albano, M. Martinez-Tristani,
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More information